 |
|
|
|
|
Volume 7, Issue 3
|
Two Drugs and One Target: Women with HER2+ Breast Cancer
Reported by Kimberly Martin
February 29, 2008
Scientists have uncovered molecular and genetic approaches to identify specific genes, proteins, and molecular pathways that are important for cancer development, growth, and survival. Understanding these biological mechanisms and how they relate to cancer has been a key factor in the development and delivery of new biologic cancer therapies, especially for breast cancer, which is the most frequently diagnosed form of cancer in women worldwide.
Two Drugs and One Target: Women with HER2+ Breast Cancer
|
|
|
Related Article
Cooperative Groups Help Advance Cancer Research
Reported by Brooke Hardison Wang and Aleea Farrakh
February 29, 2008
The NCI supports an average of over 1,300 clinical trials a year in the areas of prevention, screening, diagnostics, treatment, quality of life, supportive care, and genetics. Conducting clinical trials across multiple institutions in numerous locations requires a great deal of coordination to insure quality and consistency throughout all aspects of the trial, triggering the need for standing infrastructure with consistent policies. The NCI has supported the Clinical Trials Cooperative Group Program for over 50 years to fulfill this function.
Cooperative Groups Help Advance Cancer Research
|
|
Attention, Reporters...
To receive BenchMarks and the news updates as soon as they are posted to the
Web, join the NCI News distribution list.
Sign up here! |
|
|
|
|
|
